DDInter790 DDInter640
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} (Compound) resembles {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Furosemide {u} (Compound) treats {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mineral oil
Mineral oil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Furosemide {u} (Compound) treats {v} (Disease) dilated cardiomyopathy
dilated cardiomyopathy {u} (Disease) is palliated by {v} (Compound) Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Furosemide {u} (Compound) binds {v} (Gene) SLC22A11
SLC22A11 {u} (Gene) is bound by {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Furosemide {u} (Compound) binds {v} (Gene) CA6
CA6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Furosemide {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Verapamil
Verapamil {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Furosemide {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Furosemide {u} (Compound) causes {v} (Side Effect) Epigastric discomfort
Epigastric discomfort {u} (Side Effect) is caused by {v} (Compound) Olmesartan
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Furosemide (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Furosemide (Compound) treats dilated cardiomyopathy (Disease) and dilated cardiomyopathy (Disease) is palliated by Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Furosemide (Compound) binds SLC22A11 (Gene) and SLC22A11 (Gene) is bound by Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Furosemide (Compound) binds CA6 (Gene) and CA6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Encorafenib
Furosemide (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Verapamil (Compound) and Verapamil may lead to a major life threatening interaction when taken with Encorafenib
Furosemide (Compound) binds ALB (Gene) and ALB (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Furosemide (Compound) causes Epigastric discomfort (Side Effect) and Epigastric discomfort (Side Effect) is caused by Olmesartan (Compound) and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib